Skip to main content

Table 1 Baseline patient characteristics

From: Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis

Variable Abatacept Placebo p-value
n = 7 n = 3
Age (year) 39.8 ± 11.4 48.6 ± 13.9 0.32
Female (n, %) 5 (71.4) 3 (100) 1
Caucasian (n, %) 4 (57.1) 2 (66.7) 1
Disease duration 1st Raynaud’s (year) 3.9 ± 3.4 9.2 ± 3.2 0.05
Disease duration 1st non-Raynaud’s (year) 2.4 ± 1.6 8.8 ± 3.8 0.004
Scl-70+ (n, %) 4 (57) 2 (66.7) 1
mRSS, median (range) 22 (16–35) 30 (27–33) 0.05
HAQ-DI 0.6 ± 0.8 1.5 ± 1.1 0.18
Physician global VAS 37.6 ± 13.8 56.3 ± 5.5 0.57
Patient global VAS 53 ± 35.8 61.7 ± 44.8 0.75
Patient pain VAS 42.7 ± 35.3 53 ± 47.8 0.71
ESR (mm/hour) 13.7 ± 15.8 31 ± 18.5 0.17
FVC (% predicted) 77.3 ± 19 73.3 ± 27.6 0.79
DLCO (% predicted) 87 ± 17.5 80.3 ± 24 0.65
  1. Values are mean ± SD unless otherwise indicated. mRSS modified Rodnan skin score, DLCO diffusing capacity of the lung for carbon monoxide, ESR erythrocyte sedimentation rate, FVC forced vital capacity, HAQ-DI Health Assessment Questionnaire Disability Index, VAS visual analogue scale